

- N -[4-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butyl]- N' -(4-{4-[[{4-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butyl]amino}carbonyl]amino}phenoxy}phenyl)urea;
 N,N' -*trans*-1,4-cyclohexylenebis(N' -[4-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butyl]urea);
 N,N' -bis(2-{2-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]ethoxy}ethyl)benzene-1,3-disulfonamide;
 N,N' -bis(2-{2-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]ethoxy}ethyl)terephthalamide;
 N,N'' -1,8-octanediylbis[N' -(2-{2-[4-amino-2-(methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]ethoxy}ethyl)urea]; and
1-[10-(4-amino-2-ethoxymethyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)decyl]-2-ethoxymethyl-1*H*-imidazo[4,5-*c*]quinoline-4-amine;
or a pharmaceutically acceptable salt thereof.

15

18. A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 1 and a pharmaceutically acceptable carrier.

19. A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 17 and a pharmaceutically acceptable carrier.

20

20. A method of inducing ~~cytokine~~ biosynthesis in an animal comprising administering an effective amount of a compound or salt of claim 1 to the animal.

of interferon or tumor necrosis factor

25

21. The method of claim 20 wherein the compound or salt is administered topically.

22. A method of inducing ~~cytokine~~ biosynthesis in an animal comprising administering an effective amount of a compound or salt of claim 17 to the animal.

~~of IFN- α or IFN- γ~~
of interferon or tumor necrosis factor

23. The method of claim 22 wherein the compound or salt is administered topically.

24. A method of treating a viral disease in an animal comprising administering a therapeutically effective amount of a compound or salt of claim 1 ^{to} the animal.

5

25. The method of claim 24 wherein the compound or salt is administered topically.

26. A method of treating a viral disease in an animal comprising administering a therapeutically effective amount of a compound or salt of claim 17 to the animal.

10

27. The method of claim 26 wherein the compound or salt is administered topically.

28. A method of treating a neoplastic disease in an animal comprising administering a therapeutically effective amount of a compound or salt of claim 1 to the animal.

15


29. The method of claim 28 wherein the compound or salt is administered topically.

30. A method of treating a neoplastic disease in an animal comprising administering a therapeutically effective amount of a compound or salt of claim 17 to the animal.

20

31. The method of claim 30 wherein the compound or salt is administered topically.


32. A compound of Formula (II):



wherein:

- 5 A_1 is a divalent linking group selected from the group consisting of:
straight or branched chain C_{4-20} alkylene;
straight or branched chain C_{4-20} alkenylene; and
straight or branched chain C_{4-20} alkynylene;
any of which may be optionally interrupted by $-S(O)_2-$ or a protected
10 $-C(O)-$;
 n is 0 to 4;
each R' present is independently selected from the group consisting of:
halogen;
alkyl;
15 alkenyl; and
-O-alkyl;
or a pharmaceutically acceptable salt thereof.

33. A compound of Formula (III):



wherein:

- 20 A_1 is a divalent linking group selected from the group consisting of:
straight or branched chain C_{4-20} alkylene;
25 straight or branched chain C_{4-20} alkenylene; and

straight or branched chain C₄₋₂₀ alkynylene;

any of which may be optionally interrupted by -S(O)₂- or a protected

-C(O)-;

n is 0 to 4;

each R' present is independently selected from the group consisting of:

halogen;


alkyl;

alkenyl; and

-O-alkyl;

or a pharmaceutically acceptable salt thereof.

34. A compound of Formula (IV):



wherein:

A₁ is a divalent linking group selected from the group consisting of:

straight or branched chain C₄₋₂₀ alkylene;

straight or branched chain C₄₋₂₀ alkenylene; and

straight or branched chain C₄₋₂₀ alkynylene;

any of which may be optionally interrupted by -S(O)₂- or a protected

-C(O)-;

R'' is selected from the group consisting of:

-hydrogen;

-alkyl;

-alkenyl;

-aryl;

-substituted aryl;

-heteroaryl;

-substituted heteroaryl;

-alkyl-O-alkyl;
-alkyl-O-aryl;
-alkyl-O-alkenyl; and
-alkyl or alkenyl substituted by one or more substituents selected from the
5 group consisting of:

-OH;
-halogen;
-C(O)-N(R₆)₂;
-C(S)-N(R₆)₂;
10 -S(O)₂-N(R₆)₂;
-N(R₆)-C(O)-C₁₋₁₀ alkyl;
-N(R₆)-C(S)-C₁₋₁₀ alkyl;
-N(R₆)-S(O)₂-C₁₋₁₀ alkyl;
-C(O)-C₁₋₁₀ alkyl;
15 -C(O)-O-C₁₋₁₀ alkyl;
-N₃;
-aryl;
-substituted aryl;
-heteroaryl;
20 -substituted heteroaryl;
-heterocyclyl;
-substituted heterocyclyl;
-C(O)-aryl;
-C(O)-(substituted aryl);
25 -C(O)-heteroaryl; and
-C(O)-(substituted heteroaryl);


n is 0 to 4;

each R' present is independently selected from the group consisting of:

halogen;
30 alkyl;
alkenyl; and
-O-alkyl;

each R_6 is independently hydrogen or C_{1-10} alkyl;
or a pharmaceutically acceptable salt thereof.

35. A compound of Formula (V):



wherein:

A_1 is a divalent linking group selected from the group consisting of:

straight or branched chain C_{4-20} alkylene;

10 straight or branched chain C_{4-20} alkenylene; and

straight or branched chain C_{4-20} alkynylene;

any of which may be optionally interrupted by $-S(O)_2-$ or a protected
 $-C(O)-$;

R'' is selected from the group consisting of:

15 -hydrogen;

-alkyl;

-alkenyl;

-aryl;

-substituted aryl;

20 -heteroaryl;

-substituted heteroaryl;

-alkyl-O-alkyl;

-alkyl-O-aryl;

-alkyl-O-alkenyl; and

25 -alkyl or alkenyl substituted by one or more substituents selected from the
group consisting of:

-OH;

-halogen;

$-C(O)-N(R_6)_2$

~~5 -C(S)N(R₆)₂;
 -S(O)₂-N(R₆)₂;
 -N(R₆)-C(O)-C₁₋₁₀ alkyl;
 -N(R₆)-C(S)-C₁₋₁₀ alkyl;
 -N(R₆)-S(O)₂-C₁₋₁₀ alkyl;
 -C(O)-C₁₋₁₀ alkyl;
 -C(O)-O-C₁₋₁₀ alkyl;
 -N₃;
 -aryl;
 10 -substituted aryl;
 -heteroaryl;
 -substituted heteroaryl;
 -heterocyclyl;
 -substituted heterocyclyl;
 15 -C(O)-aryl;
 -C(O)-(substituted aryl);
 -C(O)-heteroaryl; and
 -C(O)-(substituted heteroaryl);
 n is 0 to 4;
 20 each R' present is independently selected from the group consisting of:
 halogen;
 alkyl;
 alkenyl; and
 -O-alkyl;
 25 each R₆ is independently hydrogen or C₁₋₁₀ alkyl,
 or a pharmaceutically acceptable salt thereof.~~